Loading...
•
Sep 30, 2024
Sera Prognostics Q3 2024 Earnings Report
Reported financial results for the third quarter of 2024 ended September 30, 2024.
Key Takeaways
Sera Prognostics reported third quarter 2024 revenue of $29,000, a decrease from $42,000 in the same period of 2023. The net loss for the quarter was $7.9 million, compared to $7.2 million for the prior-year period.
Data analysis for full PRIME study underway after database was locked in September and now seeking publication of results in connection with key pregnancy and maternal health conferences in early 2025.
Awareness campaign activated with TV programs by Viewpoint with Dennis Quaid and Empowered with Meg Ryan.
Beginning October 1, 2024, began enabling access to PreTRM® testing through the Company’s website, with home sample collection.
Predictive analytics offering is now in beta testing, engaging women with informative reports based on the data from millions of pregnancy experiences, and personalized insights into pregnancies like theirs.
Sera Prognostics
Sera Prognostics
Forward Guidance
The company is putting in place the key prerequisites for commercial success in anticipation of PRIME study results achieving publication and further illustrating the benefits of PreTRM capabilities and test-and-treat strategy.
Positive Outlook
- Publication of PRIME study results.
- Expanded awareness and care guidelines.
- Multi-pronged approach to the maternal care market.
- Sales inflection in the business.
- More profitable margin and revenue growth.
Challenges Ahead
- Net losses
- Need to raise more capital
- Revenues from the PreTRM Test representing substantially all Company revenues to date
- Need for broad scientific and market acceptance of the PreTRM Test
- Potential third-party payer coverage and reimbursement